

# Treating Stress and Anxiety with Functional Medicine

By James Greenblatt, MD

## Complete References

1. American Psychological Association. Apa.org. Published October, 2020. Accessed July 1, 2021. <https://www.apa.org/news/press/releases/stress/2020/sia-mental-health-crisis.pdf>
2. McEwen BS, et al. Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. *Neuropharmacology*. 2012;62(1):3-12.
3. Hoffer A, Prousky J. Successful treatment of schizophrenia requires optimal daily doses of vitamin B3. *Altern Med Rev*. 2008;13(4):287-291.
4. Periyasamy S, et al. Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study. *JAMA Psychiatry*. 2019;76(10):1026-1034.
5. Xu XJ, Jiang GS. Niacin-respondent subset of schizophrenia – a therapeutic review. *Eur Rev Med Pharmacol Sci*. 2015;19(6):988-997
6. Jonsson BH. Nicotinic Acid Long-Term Effectiveness in a Patient with Bipolar Type II Disorder: A Case of Vitamin Dependency. *Nutrients*. 2018;10(2):134
7. Woolley DW. Tranquilizing and antiserotonin activity of nicotinamide. *Science*. 1958;128(3334):1277-1278.
8. Möhler H, et al. Nicotinamide is a brain constituent with benzodiazepine-like actions. *Nature*. 1979;278(5704):563-565.
9. Slater P, Longman DA. Effects of diazepam and muscimol on GABA-mediated neurotransmission: interactions with inosine and nicotinamide. *Life Sci*. 1979;25(23):1963-1967.



10. Kennedy B, Leonard BE. Similarity between the action of nicotinamide and diazepam on neurotransmitter metabolism in the rat [proceedings]. *Biochem Soc Trans*. 1980;8(1):59-60.
11. Lapin IP. Nicotinamide, inosine and hypoxanthine, putative endogenous ligands of the benzodiazepine receptor, opposite to diazepam are much more effective against kynurenine-induced seizures than against pentylenetetrazol-induced seizures. *Pharmacol Biochem Behav*. 1981;14(5):589-593.
12. Lapin IP. Non-specific, non-selective and mild increase in the latency of pentylenetetrazol seizures produced by large doses of the putative endogenous ligands of the benzodiazepine receptor. *Neuropharmacology*. 1981;20(8):781-786.
13. Fomenko AI, Donchenko GV, Stepanenko SP. Vliianie otmeny fenazepamama i nikotinamida na sostoianie sistem retseptsii benzodiazepinov i NAD [Effect of withdrawal of phenazepam and nicotinamide on the status of the system of reception of benzodiazepines and NAD]. *Ukr Biokhim Zh (1978)*. 1996;68(5):20-25.
14. Akhundov RA, Dzhafarova SA, Aliev AN. Izyskanie novykh protivosudorozhnykh sredstv na osnove nikotinamida [The search for new anticonvulsant agents based on nicotinamide]. *Eksp Klin Farmakol*. 1992;55(1):27-29.
15. Fomenko AI, Stepanenko SP, Donchenko GV, Khalmuradov AG. Soliubilizatsiia tsentral'nogo retseptora benzodiazepinov i izuchenie ego vzaimodeistviia s nikotinamidom [Solubilization of the central benzodiazepine receptor and study of its interaction with nicotinamide]. *Biokhimiia*. 1989;54(3):381-386.
16. Chweh AY, Swinyard EA, Wolf HH. gamma-Aminobutyric acid modulation of benzodiazepine receptor binding in vitro does not predict the pharmacologic activity of all benzodiazepine receptor ligands. *Neurosci Lett*. 1985;54(2-3):173-177.  
doi:10.1016/s0304-3940(85)80074-4
17. Wright J. Treatment of Chronic Anxiety and Associated Physical Complaints with Niacinamide and Essential Fatty Acids: Two Cases. *J Orthomol Med*. 1992;7(3):182-186.
18. Prousky JE. Niacinamide's Potent role in Alleviating Anxiety with its Benzodiazepine-like Properties: A Case Report. *J Orthomol Med*. 2004;19(2):104-110.
19. Prousky JE. Supplemental Niacinamide Mitigates Anxiety Symptoms: Three Case Reports. *J Orthomol Med*. 2005;20(3):167-178.
20. Prousky JE. An N-of-1 Placebo-Controlled Trial in Clinical Practice: Testing the Effectiveness of Oral Niacinamide (Nicotinamide) for the Treatment of Anxiety. *J Orthomol Med*. 2010;25(4):195-213.
21. Cunningham JJ. Micronutrients as nutraceutical interventions in diabetes mellitus. *J Am Coll Nutr*. 1998;17(1):7-10. doi:10.1080/07315724.1998.10718729
22. Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. *Inflamm Res*. 1996;45(7):330-334.

23. Blumberg JB, Frei B, Fulgoni VL, Weaver CM, Zeisel SH. Contribution of Dietary Supplements to Nutritional Adequacy in Various Adult Age Groups. *Nutrients*. 2017;9(12):1325. Published 2017 Dec 6.
24. al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. *Am J Kidney Dis*. 1994;24(5):737-752.
25. Eaton SB, Eaton SB 3rd. Paleolithic vs. modern diets--selected pathophysiological implications. *Eur J Nutr*. 2000 Apr;39(2):67-70. doi: 10.1007/s003940070032. PMID: 10918987.
26. Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of magnesium deficiency. *J Am Coll Nutr*. 2009;28(2):131-141.
27. Weber A, Murray JM. Molecular control mechanisms in muscle contraction. *Physiol Rev*. 1973;53(3):612-673.
28. Yamanaka R, Tabata S, Shindo Y, et al. Mitochondrial Mg(2+) homeostasis decides cellular energy metabolism and vulnerability to stress. *Sci Rep*. 2016;6:30027.
29. Kirkland AE, Sarlo GL, Holton KF. The Role of Magnesium in Neurological Disorders. *Nutrients*. 2018;10(6):730.
30. Shahi A, Aslani S, Ataollahi M, Mahmoudi M. The role of magnesium in different inflammatory diseases. *Inflammopharmacology*. 2019;27(4):649-661.
31. Nielsen FH. Dietary Magnesium and Chronic Disease. *Adv Chronic Kidney Dis*. 2018;25(3):230-235.
32. Cernak I, Savic V, Kotur J, et al. Alterations in magnesium and oxidative status during chronic emotional stress. *Magnes Res*. 2000;13(1):29-36.
33. Seelig MS. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). *J Am Coll Nutr*. 1994;13(5):429-446.
34. Wacker WE, Parisi AF. Magnesium metabolism. *N Engl J Med*. 1968;278(13):712-717.
35. Seelig MS, Berger AR, Spielholz N. Latent tetany and anxiety, marginal magnesium deficit, and normocalcemia. *Dis Nerv Syst*. 1975;36(8):461-465.
36. Botturi A, et al. The Role and the Effect of Magnesium in Mental Disorders: A Systematic Review. *Nutrients*. 2020;12(6):1661.
37. Rajizadeh A, Mozaffari-Khosravi H, Yassini-Ardakani M, Dehghani A. Effect of magnesium supplementation on depression status in depressed patients with magnesium deficiency: A randomized, double-blind, placebo-controlled trial. *Nutrition*. 2017;35:56-60.

38. Tarleton EK, et al. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. *PLoS One*. 2017;12(6):e0180067.
39. Pouteau E, Kabir-Ahmadi M, Noah L, et al. Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial. *PLoS One*. 2018;13(12):e0208454.
40. Sartori SB, Whittle N, Hetzenauer A, Singewald N. Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. *Neuropharmacology*. 2012;62(1):304-312.
41. Boyle NB, Lawton C, Dye L. The Effects of Magnesium Supplementation on Subjective Anxiety and Stress-A Systematic Review. *Nutrients*. 2017;9(5):429.
42. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. *Nat Rev Cardiol*. 2018;15(4):215-229.
43. Antoni MH, Dhabhar FS. The impact of psychosocial stress and stress management on immune responses in patients with cancer. *Cancer*. 2019;125(9):1417-1431.
44. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. *Curr Mol Med*. 2008;8(4):247-252.
45. Cohen S, Williamson GM. Stress and infectious disease in humans. *Psychol Bull*. 1991;109(1):5-24.
46. Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. *Autoimmun Rev*. 2008;7(3):209-213.
47. Turner RJ, Wheaton B, Lloyd DA. The Epidemiology of Social Stress. *Am Sociol Rev*. 1995;60(1):104-125.
48. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of *Withania somnifera*: an experimental study using a rat model of chronic stress. *Pharmacol Biochem Behav*. 2003;75(3):547-555.
49. Priyanka G, Anil Kumar B, Lakshman M, Manvitha V, Kala Kumar B. Adaptogenic and Immunomodulatory Activity of Ashwagandha Root Extract: An Experimental Study in an Equine Model. *Front Vet Sci*. 2020;7:541112.
50. Lopresti AL, et al. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (*Withania somnifera*) extract: A randomized, double-blind, placebo-controlled study. *Medicine (Baltimore)*. 2019;98(37):e17186.
51. Choudhary D, Bhattacharyya S, Joshi K. Body Weight Management in Adults Under Chronic Stress Through Treatment With Ashwagandha Root Extract: A Double-Blind, Randomized, Placebo-Controlled Trial. *J Evid Based Complementary Altern Med*. 2017;22(1):96-106.

52. Auddy B, Hazra J, Mitra A. A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study. *JANA*. 2008;11(1):51-57.
53. Chengappa KNR, Brar JS, Gannon JM, Schlicht PJ. Adjunctive Use of a Standardized Extract of Withania somnifera (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. *J Clin Psychiatry*. 2018;79(5):17m11826.
54. Gannon JM, Brar J, Rai A, Chengappa KNR. Effects of a standardized extract of Withania somnifera (Ashwagandha) on depression and anxiety symptoms in persons with schizophrenia participating in a randomized, placebo-controlled clinical trial. *Ann Clin Psychiatry*. 2019;31(2):123-129.
55. Agnihotri AP, Sontakke SD, Thawani VR, Saoji A, Goswami VS. Effects of Withania somnifera in patients of schizophrenia: a randomized, double blind, placebo controlled pilot trial study. *Indian J Pharmacol*. 2013;45(4):417-418.
56. Jahanbakhsh SP, et al. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. *Complement Ther Med*. 2016;27:25-29.
57. Andrade C, Aswath A, Chaturvedi SK, Srinivasa M, Raguram R. A double-blind, placebo-controlled evaluation of the anxiolytic efficacy of an ethanolic extract of withania somnifera. *Indian J Psychiatry*. 2000;42(3):295-301.
58. Cooley K, Szczurko O, Perri D, et al. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. *PLoS One*. 2009;4(8):e6628. Published 2009 Aug 31.
59. Langade D, et al. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study. *Cureus*. 2019;11(9):e5797. Published 2019 Sep 28.
60. Fuladi S, et al. Assessment of Withania somnifera root extract efficacy in patients with generalized anxiety disorder: A randomized double-blind placebo-controlled trial [published online ahead of print, 2020 Apr 13]. *Curr Clin Pharmacol*. 2020;

